Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE013 (USA) (Dr. Clarke)
· consented 2022-03-23
Adverse events
4
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-05-16 (study day 42); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-05-27 (study day 53); relationship: N
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-07-23 (study day 110); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-09-20 (study day 169); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.